Akèy › Kansè nan tete › Virginia › Richmond
Etid klinik pou Kansè nan tete nan Richmond, VA
26 etid pou Kansè nan tete ap chèche patisipan nan sit nan ak bò kote Richmond (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
The Vanguard Study: Testing a New Way to Screen for Cancer
Ap rekriteVolontè an sante akeyi
- VCU Massey Cancer Center at Stony Point, Richmond
- VCU Massey Comprehensive Cancer Center, Richmond
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
Ap rekriteFaz 3
- Bon Secours Virginia Health System, Midlothian · 11 mi lwen
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- Bon Secours Richmond Community Hospital, Richmond
- Bon Secours Saint Mary's Hospital, Richmond
- Bon Secours Cancer Institute at Reynolds Crossing, Richmond
- ak 3 plis
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
Ap rekriteFaz 2
- Virginia Cancer Institute, Richmond
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
Ap rekriteFaz 3
- VCU Health Adult Outpatient Pavillion ( Site 0070), Richmond
- Bon Secours St. Francis Medical Center-Oncology Research ( Site 0015), Midlothian · 11 mi lwen
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
Ap rekriteFaz 3
- Research Site, Midlothian · 11 mi lwen
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Ap rekriteFaz 3
- Bon Secours Cancer Institute at St. Francis ( Site 0048), Midlothian · 11 mi lwen
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
Ap rekriteFaz 3
- Clinical Trial Site, Midlothian · 11 mi lwen
Cardiovascular Health Education Via Virtual Reality for Breast Cancer Survivors Receiving Anthracyclines or Trastuzumab
Ap rekrite
- Adult Outpatient Pavilion, Richmond
- Cellular Immunotherapies and Transplant Department, Richmond
- VCU Health at Stony Point, Richmond
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
Ap rekriteFaz 3
- Bon Secours Cancer Institute at St. Mary's, Richmond
- Bon Secours Cancer Institute at Memorial Regional, Mechanicsville · 6 mi lwen
- Bon Secours St. Francis Medical Center, Midlothian · 11 mi lwen
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Ap rekriteFaz 3
- Virginia Cancer Institute, Richmond
A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer
Ap rekriteFaz 3
- Research Site, Midlothian · 11 mi lwen
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Ap rekriteFaz 3
- Bon Secours Richmond Community Hospital, Richmond
- Bon Secours Saint Mary's Hospital, Richmond
- Bon Secours Cancer Institute at Reynolds Crossing, Richmond
- ak 4 plis
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
Ap rekriteFaz 2/3
- Bon Secours St. Francis Medical Center, Midlothian · 11 mi lwen
E-Mindfulness Approaches for Living After Breast Cancer
Ap rekriteFaz 3
- Bon Secours Richmond Community Hospital, Richmond
- Bon Secours Saint Mary's Hospital, Richmond
- Virginia Cancer Institute, Richmond
- ak 4 plis
Partial Breast Re-irradiation Using Ultra Hypofractionation (PRESERVE)
Ap rekrite
- Virgina Community University Massey Comprehensive Cancer Center, Richmond
Study to Evaluate the Feasibility of Twice Daily Use of Topical Azelaic Acid in Breast Cancer Patients Undergoing Radiation
Ap rekriteFaz 1
- Virginia Commonwealth University, Richmond
Pre-Operative Window of ET to Inform RT Decisions (POWER II)
Ap rekriteFaz 3
- Virginia Commonwealth University, Richmond
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
Ap rekriteFaz 3
- Bon Secours St. Francis Medical Oncology Center, Midlothian · 11 mi lwen
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
Ap rekriteFaz 3
- Bon Secours Cancer Institute at Memorial Regional Medical Center, Mechanicsville · 6 mi lwen
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
Ap rekriteFaz 3
- Bon Secours Saint Mary's Hospital, Richmond
- Bon Secours Cancer Institute at Reynolds Crossing, Richmond
- Bon Secours Memorial Regional Medical Center, Mechanicsville · 6 mi lwen
- ak 1 plis
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Ap rekriteEtid obsèvasyon
- VCU Massey Cancer Center at Stony Point, Richmond
- Virginia Commonwealth University/Massey Cancer Center, Richmond
PAS 1ml Magtrace® for Sentinel Lymph Node Biopsy in Breast Cancer Patients
Ap rekriteEtid obsèvasyon
- VCU Massey Comprehensive Cancer Center, Richmond
EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)
Ap rekriteEtid obsèvasyon
- VCU Massey Comprehensive Cancer Center, Richmond
- Bon Secours Cancer Institute at St. Francis, Midlothian · 11 mi lwen
ASHBY: Accelerated Super-Hypofractionated Breast Brachytherapy
Ap rekriteFaz 2
- Virginia Commonwealth University, Richmond
CONTIGO - A Narrative Intervention to Enhance Genetic Counseling and Testing
Ap rekriteVolontè an sante akeyi
- Virginia Commonwealth University, Richmond
Etid Kansè nan tete nan lòt vil
- New York City, NY136 etid
- Houston, TX126 etid
- Boston, MA112 etid
- Nashville, TN81 etid
- Los Angeles, CA73 etid
- Edison, NJ68 etid
- St. Louis, MO64 etid
- Queens, NY64 etid
- Durham, NC64 etid
- Chicago, IL59 etid
- Philadelphia, PA56 etid
- Dallas, TX55 etid
Lòt etid nan Richmond
- Kansè Poumon ki pa ti selil25 etid
- Kansè pwostat19 etid
- Ensifizyans kadyak16 etid
- Kansè poumon14 etid
- Maladi kadyovaskilè13 etid
- Kansè kolorektal13 etid
- Maladi fwa steatotik12 etid
- Leksemi mieloïd egi12 etid
- Kansè Metastatik12 etid
- Karsinòm selil skuamèz tèt ak kou12 etid
- Melanom11 etid
- Obèsite11 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.